COST OF TREATMENT IN A MEDICAL INTENSIVE- CARE UNIT - A COMPARISON OFTHE DATA FOR 1992 AND 1997

Background and objective: Treatment in an intensive care unit (ICU) is very expensive. Aim of this study was to determine the exact composit ion of costs and to analyse what factors are responsible for the rise in costs over the last 5 years. Methods: In a prospective investigatio n all 790 patients who had been treated at the ICU of the Medical Depa rtment of Frankfurt University during 1992 were included, findings bei ng compared with data on all 208 patients treated in the ICU in May an d lune 1997. All important diagnostic and therapeutic measures were qu antitatively determined each day. Results: The mean age of the ICU pat ients rose in the 5 years from 55 to 59 years (P < 0.001). Mean period of stay in the ICU remained unchanged (4.1 days), total duration of h ospital stay (15 and 12 days, respectively), and treatment intensity ( sum of points according to the >>Therapeutic Intervention Scoring Syst em<< per ICU stay: 96 and 77, respectively). The mortality rate in the ICU fell from 16.3% to 10.6% (P = 0.02), hospital mortality rate from 23% to 14% (P = 0,01). Total cost rose from DM 797 860 to DM 1 148 94 5 per 100 patients (+44%). Of this total, personnel costs were DM 286 885 in 1992 and 356 091 in 1997 (+24%), costs for apparatus-based diag nostic and therapeutic tests were DM 169 743 and 245 156, respectively (+44%), DM 98 496 and 129 222 for drugs (+31%), and DM 60 399 and 186 671 (+209%) for blood and clotting products tin each category per 100 patients). Per case costs rose from DM 7970 to 11 489, per day costs from DM 1943 to 2831. 90% of cost increases were due to new strategies in the treatment of patients with myocardial infarctions and those wi th severe clotting disorders and a rise in personnel costs. Conclusion : The costs of a stay in the ICU has greatly increased over the last 5 years, the main causes being a change to new forms of treatment, espe cially in patients with myocardial infarction and those with haemophil ia.